Fiche publication
Date publication
octobre 2019
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUENOT Dominique
,
Dr GUERIN Eric
,
Dr PENCREACH Erwan
,
Dr REITA Damien
Tous les auteurs :
Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D
Lien Pubmed
Résumé
Advanced colorectal cancer has a poor prognosis because of metastasis formation and resistance to combined therapies. Downstream of PI3K/Akt and Ras/MAPK pathways, the mTOR kinase plays a decisive role in treatment failure. We previously established that irinotecan has antiangiogenic properties and it is known that new mammalian target of rapamycin (mTOR) catalytic AZD inhibitors, unlike rapamycin, target both mTORC1 and mTORC2. Thus, we hypothesized that the complete inhibition of the PI3K/AKT/mTOR/HIF-1α axis with mTOR catalytic inhibitors and low doses of irinotecan may have antitumor effects. We showed that the AZD8055 and AZD2014 inhibitors were much more potent than rapamycin to reduce cell viability of four colon cell lines. On the other hand, whereas AZD2014 alone inhibits migration by 40%, the drug combination led to 70% inhibition. Similarly, neither irinotecan nor AZD2014 significantly reduced cell invasion, whereas a combination of the two inhibits invasion by 70%. In vivo, irinotecan and AZD2014 combination drastically reduced ectopic patient-derived colon tumor growth and this combination was more potent than Folfox or Folfiri. Finally, the combination totally inhibited liver and lung metastases developed from orthotopic implantation of SW480 cells. Thus, the use of mTOR catalytic inhibitors, in association with other chemotherapeutic agents like irinotecan at low doses, is potentially a hope for colon cancer treatment.
Mots clés
AZD2014, Irinotecan, colon cancer, mTOR, metastasis, orthotopic xenograft
Référence
Cancers (Basel). 2019 Oct 17;11(10):
